Free Trial
NASDAQ:PBLA

Panbela Therapeutics (PBLA) Stock Price, News & Analysis

Panbela Therapeutics logo
$0.27 +0.11 (+65.65%)
As of 03:45 PM Eastern

About Panbela Therapeutics Stock (NASDAQ:PBLA)

Key Stats

Today's Range
$0.16
$0.28
50-Day Range
$0.16
$0.32
52-Week Range
$0.15
$0.47
Volume
9,790 shs
Average Volume
18,353 shs
Market Capitalization
$1.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Panbela Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
2nd Percentile Overall Score

PBLA MarketRank™: 

Panbela Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Panbela Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.00% of the float of Panbela Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Panbela Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Panbela Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Panbela Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.00% of the float of Panbela Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Panbela Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Search Interest

    2 people have searched for PBLA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Panbela Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.01% of the stock of Panbela Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 4.37% of the stock of Panbela Therapeutics is held by institutions.

  • Read more about Panbela Therapeutics' insider trading history.
Receive PBLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PBLA Stock News Headlines

Panbela Therapeutics Announces Q3 2024 Financial Results
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
See More Headlines

PBLA Stock Analysis - Frequently Asked Questions

Panbela Therapeutics' stock was trading at $0.38 at the beginning of 2025. Since then, PBLA stock has decreased by 28.8% and is now trading at $0.2705.

Panbela Therapeutics, Inc. (NASDAQ:PBLA) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($159.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($94.20) by $64.80.

Panbela Therapeutics's stock reverse split before market open on Thursday, January 18th 2024.The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Panbela Therapeutics investors own include Tesla (TSLA), Recursion Pharmaceuticals (RXRX), Aridis Pharmaceuticals (ARDS), Pacific Biosciences of California (PACB), Ginkgo Bioworks (DNA), Tilray Brands (TLRY) and Agnico Eagle Mines (AEM).

Company Calendar

Last Earnings
8/10/2023
Today
7/10/2025
Next Earnings (Estimated)
7/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PBLA
CIK
1029125
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($71.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$25.26 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-302.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.26
Quick Ratio
0.26

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($18.37) per share
Price / Book
-0.01

Miscellaneous

Outstanding Shares
4,855,000
Free Float
4,855,000
Market Cap
$1.06 million
Optionable
Not Optionable
Beta
1.34
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:PBLA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners